PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomide.

Saved in:
Bibliographic Details
Title: PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomide.
Authors: Onishi S; NINDS, NIH., Jayamohan S; University of Texas Health San Antonio., Chowdhury A; NINDS, NIH., Rivas S; NINDS, NIH., Otani Y; University of Texas Health Science Center at Houston., Murphy SA; Augusta University Medical Center., Rivera-Caraballo KA; Augusta University Medical Center., Walbridge S; NINDS, NIH., Shah AH; NINDS, NIH., Sisay B; National Human Genome Research Institute, National Institutes of Health., Maric D; NINDS, NIH., Elkahloun A; National Human Genome Research Institute, National Institutes of Health., Johnson K; NINDS, NIH., Heiss J; NINDS, NIH., Lee TJ; University of Texas Health Science Center at Houston., Kumbar SG; University of Nebraska Medical Center., Brown DA; NINDS, NIH., Yoo JY; University of Texas Health Science Center at Houston., Brenner A; Mays Cancer Center at University of Texas Health San Antonio., Kaur B; Augusta University Medical Center., Sareddy GR; University of Texas Health San Antonio., Banasavadi-Siddegowda YK; NINDS, NIH.
Source: Research square [Res Sq] 2025 Feb 10. Date of Electronic Publication: 2025 Feb 10.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101768035 Publication Model: Electronic Cited Medium: Internet ISSN: 2693-5015 (Electronic) Linking ISSN: 26935015 NLM ISO Abbreviation: Res Sq Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2693-5015
DOI:10.21203/rs.3.rs-5936706/v1